J&J’s amivantamab (Rybrevant Faspro) shows a 42% response rate in advanced head & neck cancer, boosting FDA approval odds—see ...

Head and neck cancer is the sixth most common cancer worldwide, and it affects around 12,800 people in the UK each year.

An injection that eradicated entire tumours in patients with otherwise treatment-resistant cancers in a trial has been ...

Cognitive Function as a Predictor of Survival in Patients With Recurrent Malignant Glioma PURPOSE: Earlier detection of head and neck cancer recurrence may improve survival. We evaluated the ability ...

Head and neck cancer is the sixth most common cancer worldwide, and it affects around 12,800 people in the UK each year.

Please provide your email address to receive an email when new articles are posted on . A mouthwash-based biomarker test has demonstrated efficacy for detecting risk of head and neck cancer recurrence ...

Patients who have a higher risk of head and neck cancer recurrence can expect more — and sooner — monitoring of their disease. A mouthwash-based test could lend insight into which patients with head ...

Elizabeth Franzmann, MD, was co-corresponding author of a recent clinical trial testing an oral rinse to detect biomarkers associated with recurrence in head and neck cancers. MIAMI, FLORIDA ...